Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells

OncoImmunology

Volumn 7, Issue 7, 2018, Pages

  Jung, Keunok ^a   Ha, Ji Hee ^a   Kim, Jung Eun ^a   Kim, Jeong Ah ^a   Kim, Ye Jin ^a   Kim, Chul Ho ^a,b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

anti tumor therapy; Immunoglobulin heterodimeric Fc; Inflammation and cancer; Interleukin 12; large established immunogenic tumors; memory CD8+ T cells; Models of immunostimulation; monovalent binding format; Therapeutic antibodies

Indexed keywords

CD8 ANTIGEN; CYTOKINE; FUSION PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HALF LIFE TIME; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHARMACOKINETICS; PROTEIN EXPRESSION;

EID: 85042908489     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2018.1438800     Document Type: Article

References (46)

1. Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2015;22:237–46. doi:10.1038/cdd.2014.134. PMID:25190142.
2. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133–46. doi:10.1038/nri1001. PMID:12563297.
3. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012;13:722–8. doi:10.1038/ni.2366. PMID:22814351.
4. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015;21:719–29. doi:10.1038/nm.3895. PMID:26121196.
5. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012;12:749–61. doi:10.1038/nri3307. PMID:23080391.
6. Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol 2013;13:777–89. doi:10.1038/nri3536. PMID:24113868.
7. Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL. Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol 2006;177:7515–9. doi:10.4049/jimmunol.177.11.7515. PMID:17114419.
8. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007;27:281–95. doi:10.1016/j.immuni.2007.07.010. PMID:17723218.
9. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155–68. doi:10.1016/S1359-6101(01)00032-6. PMID:11900991.
10. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409–17. PMID:9815699.
11. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541–8. PMID:9326219.
12. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014;63:419–35. doi:10.1007/s00262-014-1523-1. PMID:24514955.
13. Kiefer JD, Neri D. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev 2016;270:178–92. doi:10.1111/imr.12391. PMID:26864112.
14. Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006;119:2205–12. doi:10.1002/ijc.22101. PMID:16823838.
15. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264–9. doi:10.1038/nbt0302-264. PMID:11875427.
16. Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 2012;18:4092–103. doi:10.1158/1078-0432.CCR-12-0282. PMID:22693354.
17. Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 2014;5:1869–84. doi:10.18632/oncotarget.1853. PMID:24681847.
18. Peng LS, Penichet ML, Morrison SL. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 1999;163:250–8. PMID:10384123.
19. Helguera G, Rodriguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther 2006;5:1029–40. doi:10.1158/1535-7163.MCT-05-0488. PMID:16648575.
20. Starbeck-Miller GR, Xue HH, Harty JT. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J Exp Med 2014;211:105–20. doi:10.1084/jem.20130901. PMID:24367005.
21. Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, Familletti PC, Gately MK, Gubler U. Cloning and expression of murine IL-12. J Immunol 1992;148:3433–40. PMID:1350290.
22. Ha JH, Kim JE, Kim YS. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front Immunol 2016;7:394. doi:10.3389/fimmu.2016.00394. PMID:27766096.
23. Choi HJ, Kim YJ, Choi DK, Kim YS. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening. PLoS One 2015;10:e0145349. doi:10.1371/journal.pone.0145349. PMID:26675656.
24. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012;189:3430–8. doi:10.4049/jimmunol.1200356. PMID:22956577.
25. Choi HJ, Kim YJ, Lee S, Kim YS. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther 2013;12:2748–59. doi:10.1158/1535-7163.MCT-13-0628. PMID:24132142.
26. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992;148:3125–32.
27. Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 1993;4:230–5. doi:10.1021/bc00021a008. PMID:8324014.
28. Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A 2015;112:3320–5. doi:10.1073/pnas.1416159112. PMID:25733854.
29. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160–70. doi:10.1016/j.ccr.2010.06.014. PMID:20708157.
30. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223–30. doi:10.1084/jem.178.4.1223. PMID:8104230.
31. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697–706. PMID:7913943.
32. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001;61:1095–9. PMID:11221838.
33. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565–70. doi:10.1126/science.1203486. PMID:21436444.
34. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 2016;16:112–23. doi:10.1038/nri.2015.9. PMID:26806484.
35. Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, Kim Y, Song H, Bogen B, Choi I. Tumor cells loaded with alpha-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunol Lett 2013;156:132–9. doi:10.1016/j.imlet.2013.10.002. PMID:24148970.
36. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010;17:616–23. doi:10.1038/cdd.2009.206. PMID:20075940.
37. Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002;110:983–92. doi:10.1172/JCI0215950. PMID:12370276.
38. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010;115:1678–89. doi:10.1182/blood-2009-06-227546. PMID:19903895.
39. Bachmann MF, Wolint P, Schwarz K, Jager P, Oxenius A. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 2005;175:4686–96. doi:10.4049/jimmunol.175.7.4686. PMID:16177116.
40. Huster KM, Busch V, Schiemann M, Linkemann K, Kerksiek KM, Wagner H, Busch DH. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A 2004;101:5610–5. doi:10.1073/pnas.0308054101. PMID:15044705.
41. Kohlhapp FJ, Zloza A, O'Sullivan JA, Moore TV, Lacek AT, Jagoda MC, McCracken J, Cole DJ, Guevara-Patiño JA. CD8(+) T cells sabotage their own memory potential through IFN-gamma-dependent modification of the IL-12/IL-15 receptor alpha axis on dendritic cells. J Immunol 2012;188:3639–47. doi:10.4049/jimmunol.1101580. PMID:22430740.
42. Zhang X, Starnbach MN. An Excess of the Proinflammatory Cytokines IFN-gamma and IL-12 Impairs the Development of the Memory CD8+ T Cell Response to Chlamydia trachomatis. J Immunol 2015;195:1665–75. doi:10.4049/jimmunol.1500457. PMID:26179901.
43. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000;1:31–9. doi:10.1038/35036052. PMID:11413487.
44. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003;3:721–32. doi:10.1038/nri1181. PMID:12949496.
45. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997;185:1413–22. doi:10.1084/jem.185.8.1413. PMID:9126922.
46. Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 2017;6:e1277306. doi:10.1080/2162402X.2016.1277306. PMID:28405498.